Jiajia Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jiajia Chen has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
Weichen Duan
2 shared publicationsXuenan Li
2 shared publicationsYafei Wang
2 shared publications- Ashwin Bale
Department of Chemical and Biomolecular Engineering, University of Illinois Urbana-Champaign, Urbana, IL 61801, USA
1 shared publication - Brendan A. C. Harley
University of Illinois at Urbana-Champaign
1 shared publication - Brett L. Carlson
Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota
1 shared publication
Latest Publications
- Open Access
- 1 January 2026
- Published by Ivyspring International Publisher in Theranostics
- Vol. 16 (7) , 3384-3407
STING signaling pathway: An oasis in the glioblastoma immune desert
Glioblastoma (GBM) is an “immune desert” tumor, characterized by a highly immunosuppressive tumor microenvironment (TME), which leads to immune evasion and resistance to immunotherapies. The stimulator of interferon (IFN) genes (STING) signaling pathway serves as a central hub for priming anti-tumor immunity by driving the production of type I IFNs. Thus, STING activation has shown promise for overcoming immunosuppressive TME and inhibiting tumor malignancies. Accumulating preclinical evidence shows that STING agonists exert strong antitumor effects across multiple GBM models. However, the diverse and complex roles of the STING signaling pathway in reshaping the GBM microenvironment have not been fully summarized or elucidated. This review provides an overview of the mechanisms underlying STING dysregulation and the regulatory effect of STING activation on immune cell infiltration, priming, and function. Moreover, STING agonist monotherapies, and their combination regimens or delivery via innovative platforms for GBM treatment, are critically appraised, highlighting their implications for future clinical translation.
- 1 January 2026
- Published by Ivyspring International Publisher in Theranostics
- Vol. 16 (7) , 3384-3407
Open AccessSTING signaling pathway: An oasis in the glioblastoma immune desert
Glioblastoma (GBM) is an “immune desert” tumor, characterized by a highly immunosuppressive tumor microenvironment (TME), which leads to immune evasion and resistance to immunotherapies. The stimulator of interferon (IFN) genes (STING) signaling pathway serves as a central hub for priming anti-tumor immunity by driving the production of type I IFNs. Thus, STING activation has shown promise for overcoming immunosuppressive TME and inhibiting tumor malignancies. Accumulating preclinical evidence shows that STING agonists exert strong antitumor effects across multiple GBM models. However, the diverse and complex roles of the STING signaling pathway in reshaping the GBM microenvironment have not been fully summarized or elucidated. This review provides an overview of the mechanisms underlying STING dysregulation and the regulatory effect of STING activation on immune cell infiltration, priming, and function. Moreover, STING agonist monotherapies, and their combination regimens or delivery via innovative platforms for GBM treatment, are critically appraised, highlighting their implications for future clinical translation.
- 14 October 2025
- Published by Springer Nature in Oncogene
- Vol. 44 (46) , 4462-4474
BRD4 inhibition sensitizes glioblastoma to radiotherapy by suppressing super-enhancer-driven COL1A1
Radiotherapy (RT) combined with chemotherapy is the standard treatment for newly diagnosed glioblastoma (GBM). However, the limited RT efficacy and RT-related cancer resistance have spurred interest in radiosensitizing strategies for GBM. We aimed to explore the synergistic efficacy of the bromodomain-containing protein 4 (BRD4) inhibitor I-BET151 in combination with RT for GBM therapy. We found that BRD4 upregulation after RT was correlated with GBM radiosensitivity. I-BET151 sensitized GBM cells to RT by inhibiting cell proliferation and inducing cell apoptosis, thus prolonging survival in subcutaneous and orthotopic murine GL261 GBM mouse models. In vitro, I-BET151 sensitized GBM cells to RT by suppressing proliferation, inducing apoptosis, and increasing sustainable DNA damage. Mechanistically, integrated H3K27ac ChIP-sequencing and RNA-sequencing analysis identified type I collagen (COL1A1) as a key BRD4-dependent super-enhancer (SE)-driven target post-RT, which was also validated by ChIP‒qPCR. Moreover, RNA interference-mediated COL1A1 silencing reduced proliferation, increased apoptosis, and enhanced RT-induced DNA damage, underscoring its pivotal role in BRD4-mediated radioresistance. In conclusion, BRD4 contributes to extracellular matrix remodeling and radioresistance in a SE-driven COL1A1-dependent manner. Thus, targeting BRD4 is a rational strategy to augment the efficacy of RT for GBM treatment.
- 14 October 2025
- Published by Springer Nature in Oncogene
- Vol. 44 (46) , 4462-4474
BRD4 inhibition sensitizes glioblastoma to radiotherapy by suppressing super-enhancer-driven COL1A1
Radiotherapy (RT) combined with chemotherapy is the standard treatment for newly diagnosed glioblastoma (GBM). However, the limited RT efficacy and RT-related cancer resistance have spurred interest in radiosensitizing strategies for GBM. We aimed to explore the synergistic efficacy of the bromodomain-containing protein 4 (BRD4) inhibitor I-BET151 in combination with RT for GBM therapy. We found that BRD4 upregulation after RT was correlated with GBM radiosensitivity. I-BET151 sensitized GBM cells to RT by inhibiting cell proliferation and inducing cell apoptosis, thus prolonging survival in subcutaneous and orthotopic murine GL261 GBM mouse models. In vitro, I-BET151 sensitized GBM cells to RT by suppressing proliferation, inducing apoptosis, and increasing sustainable DNA damage. Mechanistically, integrated H3K27ac ChIP-sequencing and RNA-sequencing analysis identified type I collagen (COL1A1) as a key BRD4-dependent super-enhancer (SE)-driven target post-RT, which was also validated by ChIP‒qPCR. Moreover, RNA interference-mediated COL1A1 silencing reduced proliferation, increased apoptosis, and enhanced RT-induced DNA damage, underscoring its pivotal role in BRD4-mediated radioresistance. In conclusion, BRD4 contributes to extracellular matrix remodeling and radioresistance in a SE-driven COL1A1-dependent manner. Thus, targeting BRD4 is a rational strategy to augment the efficacy of RT for GBM treatment.
- 14 February 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 16 (734) , eadj5962
Aberrant ATM signaling and homology-directed DNA repair as a vulnerability of p53-mutant GBM to AZD1390-mediated radiosensitization
ATM is a key mediator of radiation response, and pharmacological inhibition of ATM is a rational strategy to radiosensitize tumors. AZD1390 is a brain-penetrant ATM inhibitor and a potent radiosensitizer. This study evaluated the spectrum of radiosensitizing effects and the impact of TP53 mutation status in a panel of IDH1 wild-type (WT) glioblastoma (GBM) patient-derived xenografts (PDXs). AZD1390 suppressed radiation-induced ATM signaling, abrogated G 0 -G 1 arrest, and promoted a proapoptotic response specifically in p53-mutant GBM in vitro. In a preclinical trial using 10 orthotopic GBM models, AZD1390/RT afforded benefit in a cohort of TP53 -mutant tumors but not in TP53 -WT PDXs. In mechanistic studies, increased endogenous DNA damage and constitutive ATM signaling were observed in TP53 -mutant, but not in TP53 -WT, PDXs. In plasmid-based reporter assays, GBM43 ( TP53 -mutant) showed elevated DNA repair capacity compared with that in GBM14 (p53-WT), whereas treatment with AZD1390 specifically suppressed homologous recombination (HR) efficiency, in part, by stalling RAD51 unloading. Furthermore, overexpression of a dominant-negative TP53 (p53DD) construct resulted in enhanced basal ATM signaling, HR activity, and AZD1390-mediated radiosensitization in GBM14. Analyzing RNA-seq data from TCGA showed up-regulation of HR pathway genes in TP53 -mutant human GBM. Together, our results imply that increased basal ATM signaling and enhanced dependence on HR represent a unique susceptibility of TP53 -mutant cells to ATM inhibitor–mediated radiosensitization.
- 14 February 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 16 (734) , eadj5962
Aberrant ATM signaling and homology-directed DNA repair as a vulnerability of p53-mutant GBM to AZD1390-mediated radiosensitization
ATM is a key mediator of radiation response, and pharmacological inhibition of ATM is a rational strategy to radiosensitize tumors. AZD1390 is a brain-penetrant ATM inhibitor and a potent radiosensitizer. This study evaluated the spectrum of radiosensitizing effects and the impact of TP53 mutation status in a panel of IDH1 wild-type (WT) glioblastoma (GBM) patient-derived xenografts (PDXs). AZD1390 suppressed radiation-induced ATM signaling, abrogated G 0 -G 1 arrest, and promoted a proapoptotic response specifically in p53-mutant GBM in vitro. In a preclinical trial using 10 orthotopic GBM models, AZD1390/RT afforded benefit in a cohort of TP53 -mutant tumors but not in TP53 -WT PDXs. In mechanistic studies, increased endogenous DNA damage and constitutive ATM signaling were observed in TP53 -mutant, but not in TP53 -WT, PDXs. In plasmid-based reporter assays, GBM43 ( TP53 -mutant) showed elevated DNA repair capacity compared with that in GBM14 (p53-WT), whereas treatment with AZD1390 specifically suppressed homologous recombination (HR) efficiency, in part, by stalling RAD51 unloading. Furthermore, overexpression of a dominant-negative TP53 (p53DD) construct resulted in enhanced basal ATM signaling, HR activity, and AZD1390-mediated radiosensitization in GBM14. Analyzing RNA-seq data from TCGA showed up-regulation of HR pathway genes in TP53 -mutant human GBM. Together, our results imply that increased basal ATM signaling and enhanced dependence on HR represent a unique susceptibility of TP53 -mutant cells to ATM inhibitor–mediated radiosensitization.